Agios Pharmaceuticals (LSE:0HB0) - Hisse Senedi Fiyatı, Haberler ve Analizler

0HB0 Stoklara Genel Bakış

Bir biyofarmasötik şirketi olan Agios Pharmaceuticals, Inc. Amerika Birleşik Devletleri'nde hücresel metabolizma alanında ilaçlar keşfetmekte ve geliştirmektedir. Daha fazla detay

0HB0 temel anali̇z
Kar Tanesi Skoru
Değerleme	5/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	3/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 78.4% daha düşük bir oranda işlem görüyor

Gelirin yılda 55.42% oranında artması öngörülüyor

Bu yıl karlı hale geldi

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Yüksek düzeyde nakit olmayan kazançlar

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 56.7% oranında düşmesi öngörülüyor

Son 3 ayda dalgalı hisse senedi fiyatı

Hissedarlar geçen yıl sulandırıldı

Agios Pharmaceuticals, Inc. Rakipler

Genus

LSE:GNS

UK£1.1b

Bioventix

AIM:BVXP

UK£195.7m

Hikma Pharmaceuticals

LSE:HIK

UK£4.3b

PharmaEssentia

TWSE:6446

NT$193.7b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Agios Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$56.60
52 Haftanın En Yüksek Seviyesi	US$62.60
52 Haftanın En Düşük Seviyesi	US$21.03
Beta	0.75
11 Aylık Değişim	23.84%
3 Aylık Değişim	22.40%
1 Yıllık Değişim	164.17%
33 Yıllık Değişim	48.87%
5 Yıllık Değişim	70.27%
Halka arzdan bu yana değişim	-29.88%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	0HB0	GB Biotechs	GB Pazar
7D	5.5%	2.0%	1.7%
1Y	164.2%	-17.5%	8.3%

Getiri vs. Endüstri: 0HB0 geçen yıl % -17.5 oranında getiri sağlayan UK Biotechs sektörünü aştı.

Getiri vs Piyasa: 0HB0 geçen yıl % 8.3 oranında getiri sağlayan UK Piyasasını aştı.

Fiyat Oynaklığı

Is 0HB0's price volatile compared to industry and market?
0HB0 volatility
0HB0 Average Weekly Movement	7.4%
Biotechs Industry Average Movement	9.7%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: 0HB0 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 0HB0 'nin haftalık oynaklığı ( 7% ) geçen yıl boyunca sabit kaldı, ancak hala UK hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2007	385	Brian Goff	www.agios.com

Bir biyofarmasötik şirketi olan Agios Pharmaceuticals, Inc. Amerika Birleşik Devletleri'nde hücresel metabolizma alanında ilaçlar keşfetmekte ve geliştirmektedir. Lider ürünü, hemolitik anemilerin tedavisi için vahşi tip ve mutant piruvat kinaz (PK) enzimlerinin bir aktivatörü olan PYRUKYND'yi (mitapivat) içerir. Şirket, düşük riskli miyelodisplastik sendrom ve hemolitik anemilerin tedavisi için bir PK aktivatörü olan AG-946'yı ve fenilketonüri tedavisi için bir fenilalanin hidroksilaz stabilizatörü olan AG-181'i geliştirmektedir.

Agios Pharmaceuticals, Inc. Temel Bilgiler Özeti

Agios Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
0HB0 temel i̇stati̇sti̇kler
Piyasa değeri	US$3.18b
Kazançlar(TTM)	US$674.31m
Gelir(TTM)	US$32.87m

4.7x

F/K Oranı

96.6x

P/S Oranı

0HB0 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
0HB0 gelir tablosu (TTM)
Gelir	US$32.87m
Gelir Maliyeti	US$299.46m
Brüt Kâr	-US$266.58m
Diğer Giderler	-US$940.89m
Kazançlar	US$674.31m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	11.82
Brüt Marj	-811.00%
Net Kâr Marjı	2,051.38%
Borç/Özkaynak Oranı	0%

0HB0 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

0HB0 Stoklara Genel Bakış

Ödüller

Risk Analizi

Agios Pharmaceuticals, Inc. Rakipler

LSE:GNS

UK£1.1b

AIM:BVXP

UK£195.7m

LSE:HIK

UK£4.3b

TWSE:6446

NT$193.7b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Third quarter 2024 earnings released: EPS: US$16.65 (vs US$1.64 loss in 3Q 2023)

Agios Pharmaceuticals, Inc. Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

New major risk - Revenue and earnings growth

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Recent updates

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Third quarter 2024 earnings released: EPS: US$16.65 (vs US$1.64 loss in 3Q 2023)

Agios Pharmaceuticals, Inc. Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

New major risk - Revenue and earnings growth

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Forecast to breakeven in 2024

Second quarter 2024 earnings released: US$1.69 loss per share (vs US$1.51 loss in 2Q 2023)

New major risk - Revenue and earnings growth

Agios Pharmaceuticals, Inc. Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

New minor risk - Profitability

Agios Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

Forecast to breakeven in 2024

Agios Pharmaceuticals, Inc. Announces Phase 3 Energize-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

First quarter 2024 earnings released: US$1.45 loss per share (vs US$1.47 loss in 1Q 2023)

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$6.33 loss per share (vs US$4.23 loss in FY 2022)

Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Third quarter 2023 earnings released: US$1.64 loss per share (vs US$1.49 loss in 3Q 2022)

Agios Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: US$1.51 loss per share (vs US$1.68 loss in 2Q 2022)

Agios Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Agios Pharmaceuticals, Inc. Announces Board Changes

Insufficient new directors

Agios Pharmaceuticals, Inc. Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Agios Pharmaceutical's PYRUKYND® Approves in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Receives Positive Chmp Opinion for Pyrukynd® (Mitapivat) for the Treatment of Pyruvate Kinase (Pk) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Agios Pharmaceuticals, Inc. Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent a- and ß-Thalassemia

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces Management Changes, Effective August 8, 2022

Agios Presents New Clinical Data Supporting the Benefits of Pyrukynd® Treatment in Adults with PK Deficiency At European Hematology Association Annual Congress

Agios Pharmaceuticals, Inc. Announces Resignation of Bruce Car as Chief Scientific Officer, effective as of August 1, 2022

Agios Pharmaceuticals, Inc. Announces Management Changes

Agios Pharmaceuticals, Inc. Announces Executive Changes

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces Resignation of Ian T. Clark from the Board

Agios Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces FDA Approval of Pyrukynd (Mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

Insufficient new directors

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Agios Pharmaceuticals, Inc. Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition

Insufficient new directors

Forecast to breakeven in 2021

Forecast to breakeven in 2021

Agios Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Principal Accounting Officer and VP of Accounting, Treasury & Tax Carman Alenson has left the company

Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) dropped from Russell Midcap Value Index